Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib with or without Bevacizumab in Metastatic RCC
NCT00491738Phase 2Terminated
- Sponsor
- Genentech
- Start
- Aug 2007
- Primary completion
- Jan 2008
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Bevacizumab + Sunitinib with Placebo + Sunitinib (2 arms). Primary endpoint: All Adverse Events (Lab Toxicities Reported Were Only Grade 3 and Higher) at 5 months. Started Aug 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00491738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00491738.